{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:57:26Z","timestamp":1791197846011,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ek0510042"],"award-info":[{"award-number":["JP23ek0510042"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04239-6","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:54:57Z","timestamp":1781801697000},"page":"486-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status and challenges of TCR-T cell therapy for AML\/MDS"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-2826","authenticated-orcid":false,"given":"Yoshiki","family":"Akatsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4239_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1182\/blood.2023023727","volume":"144","author":"E Bernard","year":"2024","unstructured":"Bernard E, Hasserjian RP, Greenberg PL, Arango Ossa JE, Creignou M, Tuechler H, et al. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood. 2024;144:1617\u201332.","journal-title":"Blood"},{"key":"4239_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"4239_CR3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/bjh.20116","volume":"206","author":"R Ramanathan","year":"2025","unstructured":"Ramanathan R, Xie Y, Badar T, Zeidan AM, Patel SA. Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes\/neoplasms. Br J Haematol. 2025;206:1571\u201381.","journal-title":"Br J Haematol"},{"key":"4239_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","volume":"162","author":"JH Levine","year":"2015","unstructured":"Levine JH, Simonds EF, Bendall SC, Davis KL, el Amir AD, Tadmor MD, et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell. 2015;162:184\u201397.","journal-title":"Cell"},{"key":"4239_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","volume":"33","author":"O Humbert","year":"2019","unstructured":"Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, et al. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2. Leukemia. 2019;33:762\u2013808.","journal-title":"Leukemia"},{"key":"4239_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","volume":"35","author":"S Fiorenza","year":"2021","unstructured":"Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs. 2021;35:281\u2013302.","journal-title":"BioDrugs"},{"issue":"Pt 6","key":"4239_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/icb.1991.58","volume":"69","author":"H Zola","year":"1991","unstructured":"Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol. 1991;69(Pt 6):411\u201322.","journal-title":"Immunol Cell Biol"},{"key":"4239_CR8","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"4239_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1440-1711.2006.01447.x","volume":"84","author":"S Viatte","year":"2006","unstructured":"Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol. 2006;84:318\u201330.","journal-title":"Immunol Cell Biol"},{"key":"4239_CR10","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130:1985\u201394.","journal-title":"Blood"},{"issue":"737\u201352","key":"4239_CR11","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx G, Larouche JD, Durette C, Laverdure JP, Hesnard L, Vincent K, et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. 2021;54(737\u201352):e10.","journal-title":"Immunity"},{"key":"4239_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12185-008-0134-z","volume":"88","author":"K Watanabe","year":"2008","unstructured":"Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol. 2008;88:311\u201320.","journal-title":"Int J Hematol"},{"key":"4239_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101899","volume":"42","author":"J Zenga","year":"2024","unstructured":"Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV, et al. Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture. Transl Oncol. 2024;42:101899.","journal-title":"Transl Oncol"},{"key":"4239_CR14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","volume":"25","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med. 2019;25:1488\u201399.","journal-title":"Nat Med"},{"key":"4239_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.imbio.2019.05.001","volume":"224","author":"YWB Teo","year":"2019","unstructured":"Teo YWB, Linn YC, Goh YT, Li S, Ho LP. Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (Simulated Infective Protocol). Immunobiology. 2019;224:526\u201331.","journal-title":"Immunobiology"},{"key":"4239_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nbt1070","volume":"23","author":"Y Li","year":"2005","unstructured":"Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23:349\u201354.","journal-title":"Nat Biotechnol"},{"key":"4239_CR17","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1111\/cas.15954","volume":"114","author":"S Okada","year":"2023","unstructured":"Okada S, Muraoka D, Yasui K, Tawara I, Kawamura A, Okamoto S, et al. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease. Cancer Sci. 2023;114:4172\u201383.","journal-title":"Cancer Sci"},{"key":"4239_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255\u201363.","journal-title":"Blood"},{"key":"4239_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood. 2014;124:1277\u201387.","journal-title":"Blood"},{"key":"4239_CR20","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","volume":"180","author":"PF Robbins","year":"2008","unstructured":"Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180:6116\u201331.","journal-title":"J Immunol"},{"key":"4239_CR21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/gt.2009.54","volume":"16","author":"PD Peng","year":"2009","unstructured":"Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 2009;16:1042\u20139.","journal-title":"Gene Ther"},{"key":"4239_CR22","doi-asserted-by":"crossref","unstructured":"Smilauerova K, Stach M, Mucha M, Vanikova S, Rychla J, Otahal P. Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. Immunother Adv. 2025;5:ltaf022.","DOI":"10.1093\/immadv\/ltaf022"},{"key":"4239_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14:eabg8027.","journal-title":"Sci Transl Med"},{"key":"4239_CR24","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","volume":"66","author":"CJ Cohen","year":"2006","unstructured":"Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability. Cancer Res. 2006;66:8878\u201386.","journal-title":"Cancer Res"},{"key":"4239_CR25","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","volume":"67","author":"CJ Cohen","year":"2007","unstructured":"Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007;67:3898\u2013903.","journal-title":"Cancer Res"},{"key":"4239_CR26","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.4049\/jimmunol.1302074","volume":"193","author":"C Govers","year":"2014","unstructured":"Govers C, Sebestyen Z, Roszik J, van Brakel M, Berrevoets C, Szoor A, et al. TCRs genetically linked to CD28 and CD3epsilon do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J Immunol. 2014;193:5315\u201326.","journal-title":"J Immunol"},{"key":"4239_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807\u201315.","journal-title":"Nat Med"},{"key":"4239_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109055","volume":"110","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Shokrgozar MA, Evazalipour M, Roudkenar MH. CRISPR\/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study. Int Immunopharmacol. 2022;110:109055.","journal-title":"Int Immunopharmacol"},{"key":"4239_CR29","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober K, Muller TR, Gokmen F, Grassmann S, Effenberger M, Poltorak M, et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019;3:974\u201384.","journal-title":"Nat Biomed Eng"},{"key":"4239_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg7123","volume":"16","author":"BJ Mog","year":"2024","unstructured":"Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, et al. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Sci Transl Med. 2024;16:eadg7123.","journal-title":"Sci Transl Med"},{"key":"4239_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/gt.2014.30","volume":"21","author":"Y Inaguma","year":"2014","unstructured":"Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A, et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther. 2014;21:575\u201384.","journal-title":"Gene Ther"},{"key":"4239_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200797","volume":"32","author":"K Teppert","year":"2024","unstructured":"Teppert K, Yonezawa Ogusuku IE, Brandes C, Herbel V, Winter N, Werchau N, et al. CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment. Mol Ther Oncol. 2024;32:200797.","journal-title":"Mol Ther Oncol"},{"key":"4239_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04113-x","author":"YH Chang","year":"2025","unstructured":"Chang YH, Goyama S. Recent advances of cell therapies for AML\/MDS: exploring the therapeutic potential of innate immune cells in AML\/MDS. Int J Hematol. 2025. https:\/\/doi.org\/10.1007\/s12185-025-04113-x.","journal-title":"Int J Hematol"},{"key":"4239_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105002","volume":"217","author":"A Azlan","year":"2025","unstructured":"Azlan A, Zakaria N, Rafsanjani MR, Solayappan M, Yik MY, Said MSM, et al. Current progress in the elucidation of Acute Myeloid Leukemia (AML) immune landscapes. Crit Rev Oncol Hematol. 2025;217:105002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4239_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","volume":"38","author":"A Perzolli","year":"2024","unstructured":"Perzolli A, Koedijk JB, Zwaan CM, Heidenreich O. Targeting the innate immune system in pediatric and adult AML. Leukemia. 2024;38:1191\u2013201.","journal-title":"Leukemia"},{"key":"4239_CR36","doi-asserted-by":"publisher","first-page":"1193978","DOI":"10.3389\/fonc.2023.1193978","volume":"13","author":"Z Ding","year":"2023","unstructured":"Ding Z, Shi R, Hu W, Tian L, Sun R, Wu Y, et al. Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets. Front Oncol. 2023;13:1193978.","journal-title":"Front Oncol"},{"key":"4239_CR37","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2016.143180","volume":"101","author":"YS Al-Matary","year":"2016","unstructured":"Al-Matary YS, Botezatu L, Opalka B, Hones JM, Lams RF, Thivakaran A, et al. Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica. 2016;101:1216\u201327.","journal-title":"Haematologica"},{"key":"4239_CR38","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.1182\/blood-2022-168178","volume":"140","author":"AFOKV Costa","year":"2022","unstructured":"Costa AFOKV, Marani LO, Lopes IA, Binelli LS, Scheucher PS, et al. Dysregulated activating and inhibitory receptors on natural killer cells predicts immune escape and poor outcomes in acute myeloid leukemia. Blood. 2022;140:9113\u20134.","journal-title":"Blood"},{"key":"4239_CR39","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115:E4041\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4239_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081998","author":"N Sailer","year":"2022","unstructured":"Sailer N, Fetzer I, Salvermoser M, Braun M, Brechtefeld D, Krendl C, et al. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14081998.","journal-title":"Cancers (Basel)"},{"key":"4239_CR41","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1182\/blood.V126.23.1348.1348","volume":"126","author":"ROMH Jacamo","year":"2015","unstructured":"Jacamo ROMH, Zhang QI, Chachad D, Zhiquiang W, Ma W, et al. Effect of CCL2\/CCR2 blockade in acute myeloid leukemia. Blood. 2015;126:1348.","journal-title":"Blood"},{"key":"4239_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1479-5876-9-151","volume":"9","author":"B Beck","year":"2011","unstructured":"Beck B, Dorfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J Transl Med. 2011;9:151.","journal-title":"J Transl Med"},{"key":"4239_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.imlet.2010.08.002","volume":"133","author":"E Ferretti","year":"2010","unstructured":"Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett. 2010;133:99\u2013105.","journal-title":"Immunol Lett"},{"key":"4239_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","volume":"163","author":"TM Clay","year":"1999","unstructured":"Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507\u201313.","journal-title":"J Immunol"},{"key":"4239_CR45","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood-2003-05-1524","volume":"102","author":"MH Heemskerk","year":"2003","unstructured":"Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102:3530\u201340.","journal-title":"Blood"},{"key":"4239_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126\u20139.","journal-title":"Science"},{"key":"4239_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25:1064\u201372.","journal-title":"Nat Med"},{"key":"4239_CR48","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41467-025-60394-0","volume":"16","author":"F Mazziotta","year":"2025","unstructured":"Mazziotta F, Martin LE, Egan DN, Bar M, Kinsella S, Paulson KG, et al. A phase I\/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Nat Commun. 2025;16:5214.","journal-title":"Nat Commun"},{"key":"4239_CR49","doi-asserted-by":"crossref","unstructured":"Morris EC T-RR, Richardson R, et al. A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation. Blood. 2019;134 .Suppl 1: 1367.","DOI":"10.1182\/blood-2019-128044"},{"key":"4239_CR50","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, et al. Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2025;31:2365\u201374.","journal-title":"Nat Med"},{"key":"4239_CR51","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","volume":"11","author":"P van Balen","year":"2020","unstructured":"van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, et al. HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study. Front Immunol. 2020;11:1804.","journal-title":"Front Immunol"},{"issue":"2","key":"4239_CR52","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jtct.2023.12.020","volume":"30","author":"MM Al Malki","year":"2024","unstructured":"Al Malki MM, KA, Suh HC, et al. TSC-100 and TSC-101, TCR-T cell therapies that target residual recipient cells after reduced intensity conditioning transplantation, induce complete donor chimerism with favorable prognosis: early results of a phase 1 trial. Transplant Cell. 2024;30(2):S1\u20132.","journal-title":"Transplant Cell."},{"key":"4239_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.2024024105","volume":"144","author":"EF Krakow","year":"2024","unstructured":"Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, et al. HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood. 2024;144:1069\u201382.","journal-title":"Blood"},{"key":"4239_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12185-023-03621-y","volume":"118","author":"C Barakat","year":"2023","unstructured":"Barakat C, Inagaki Y, Mizuno S, Nishio N, Katsuyama N, Sato Y, et al. Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation. Int J Hematol. 2023;118:252\u201366.","journal-title":"Int J Hematol"},{"key":"4239_CR55","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","volume":"9","author":"S Gore","year":"2025","unstructured":"Gore S, Blyth E, Bleakley M, Lee K, Micklethwaite K, Gowrishankar K. Current developments in T-cell receptor therapy for acute myeloid leukemia. Blood Adv. 2025;9:3069\u201389.","journal-title":"Blood Adv"},{"key":"4239_CR56","doi-asserted-by":"publisher","first-page":"1460437","DOI":"10.3389\/fimmu.2024.1460437","volume":"15","author":"AH Kheirkhah","year":"2024","unstructured":"Kheirkhah AH, Habibi S, Yousefi MH, Mehri S, Ma B, Saleh M, et al. Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia. Front Immunol. 2024;15:1460437.","journal-title":"Front Immunol"},{"key":"4239_CR57","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/10428194.2024.2414112","volume":"66","author":"S Tharakan","year":"2025","unstructured":"Tharakan S, Tremblay D, Azzi J. Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies. Leuk Lymphoma. 2025;66:204\u201317.","journal-title":"Leuk Lymphoma"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04239-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:25Z","timestamp":1791194365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4239"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04239-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YA received honoraria and research funding from Bristol-Myers Squibb and RIKAKEN HOLDINGS Co., Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}